You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The bipartisan bill passed both the House and Senate by large margins and increases the NIH's budget by 5.4 percent over its fiscal 2018 funding level.
UCSD plans to expand the Metabolomics Workbench to include a wide range of clinical trials data including demographics and trial protocols.
The centers will generate genotype and whole-genome sequence data from the samples submitted by participants.
Applicants will be expected to develop the capacity to conduct up to 200,000 genome-wide assays per year and generate high-quality genotyping and genome sequence data.
The six-year, $190 million Somatic Cell Genome Editing program aims to remove barriers that slow the adoption of genome editing for treating patients.
In a wide-ranging discussion, the two leaders touched upon vaccine development, infant mortality, US education, research funding, machine learning, and precision medicine.
Hospital will partner with several other institutions in this effort to support data-driven research into pediatric cancers and structural birth defects.
Biotech and academic leaders met with Trump administration officials to discuss NIH funding, ScienceInsider reports.
The funding will be used to develop new software and data structures to enable researchers to use the GO data for network-based analysis.
The funding builds on more than $1.7 million already awarded to the firm, which is building a diagnostic for characterizing patients in clinical trials.
The Wall Street Journal reports that Russia's announcement of a coronavirus vaccine approval was met with concern as safety testing has not yet been completed.
New Scientist writes there aren't much data available on the accuracy of the two rapid COVID-19 tests the UK plans to roll out.
In PNAS this week: downstream effect of oncoprotein fusion, epigenetic changes influence tRNAs in colon cancer, and more.
Nature News reports that recent proposed changes to the US National Science Foundation have raised concerns about a shift away from the agency's focus on basic research.